Autonomic Nervous System Drugs Practice Questions

Q: Botulinum toxin acts on

Synapse. ***Synapse*** - **Botulinum toxin** acts by inhibiting the release of **acetylcholine** at the **neuromuscular junction**, which is a type of synapse. - This blockade of neurotransmitter release at the **presynaptic terminal** prevents muscle contraction, leading to paralysis. *Smooth muscle of intestine* - While botulinum toxin can affect smooth muscle indirectly by paralyzing the motor nerves innervating them, its primary site of action is the **synapse** itself, not directly on the muscle fibers. - The toxin primarily targets the nerve endings, rather than the mechanical contractility of the muscle cell. *Central nervous system* - **Botulinum toxin** does not readily cross the **blood-brain barrier**, meaning its primary effects are peripheral. - Its therapeutic and toxic effects are localized to the **peripheral nervous system** and neuromuscular junctions. *Sensory nerves* - **Botulinum toxin** specifically targets **motor nerve endings** to inhibit acetylcholine release, leading to muscle paralysis. - It does not directly affect the function of **sensory nerve transmission** or pain perception in the same way.

Q: Which class of drugs does botulinum toxin mimic in its action?

Anticholinergics. ***Anticholinergics*** - **Botulinum toxin** inhibits the release of **acetylcholine** from **presynaptic nerve terminals** [2] by preventing vesicle fusion, leading to muscle paralysis [1]. - While the **mechanism differs** (botulinum acts presynaptically, anticholinergics act postsynaptically at receptors), the **functional outcome** is similar: reduced cholinergic neurotransmission. - In terms of **clinical effect** at the neuromuscular junction, both reduce acetylcholine's action, making anticholinergics the closest functional parallel among the given options. *Cholinergics* - **Cholinergics** enhance acetylcholine activity, either by increasing its release, mimicking its effects at receptors, or inhibiting its breakdown. - This is the **opposite** of botulinum toxin's action, which reduces acetylcholine's impact. *Adrenergics* - **Adrenergics** stimulate the **sympathetic nervous system** via **adrenergic receptors** (α and β receptors). - They act on **norepinephrine/epinephrine pathways**, not the cholinergic system where botulinum toxin acts. *Antiadrenergic* - **Antiadrenergic drugs** block **adrenergic receptors** or inhibit sympathetic activity. - These are unrelated to botulinum toxin's effect on **cholinergic neuromuscular transmission**.

Q: Which of the following is a benzylisoquinoline muscle relaxant?

Doxacurium. ***Doxacurium*** - **Doxacurium** is a long-acting, non-depolarizing neuromuscular blocker classified as a **benzylisoquinoline** compound [1]. - These agents are known for their minimal cardiovascular effects and lack of histamine release in therapeutic doses [1]. *Vecuronium* - **Vecuronium** is an **aminosteroid** non-depolarizing neuromuscular blocker [2]. - It is known for its intermediate duration of action and minimal cardiovascular effects [1]. *Rocuronium* - **Rocuronium** is also an **aminosteroid** non-depolarizing neuromuscular blocker [2]. - It has a rapid onset of action, making it suitable for rapid sequence intubation, and can be reversed by **sugammadex**. *Pancuronium* - **Pancuronium** is an **aminosteroid** non-depolarizing neuromuscular blocker with a long duration of action [1]. - It is associated with a vagolytic effect that can cause an increase in **heart rate** and **blood pressure** [1].

Q: Besides its properties of decreasing intraocular pressure, timolol is preferred in the treatment of glaucoma because it

Produces no miosis. ***Produces no miosis*** - Timolol, a **non-selective beta-blocker**, decreases intraocular pressure without affecting pupillary size. - This is a **key advantage** in glaucoma treatment as miosis (pupil constriction) can worsen vision, especially in patients with cataracts. - Unlike **miotics** (e.g., pilocarpine), timolol does not cause pupillary constriction, making it better tolerated. *Possesses membrane stabilizing activity* - While some beta-blockers possess **membrane-stabilizing activity** (local anesthetic effect), this property is not a primary reason for timolol's preference in glaucoma. - This action is more relevant in antiarrhythmic uses of beta-blockers due to its effect on cardiac action potentials. *Increases outflow of aqueous humor* - Timolol primarily reduces intraocular pressure by **decreasing the production of aqueous humor**, not by increasing its outflow. - Drugs like **pilocarpine** (a cholinergic agonist) or **prostaglandin analogs** increase outflow. *Is a selective beta-adrenoceptor blocker* - Timolol is a **non-selective beta-blocker**, meaning it blocks both beta-1 and beta-2 adrenergic receptors. - Its non-selectivity is associated with systemic side effects (e.g., bronchospasm, bradycardia), and selective beta-blockers like **betaxolol** exist but are not the primary reason for timolol's preference in glaucoma.

Q: Which antiglaucomatous drug is known to cause spasm of accommodation?

Pilocarpine. ***Pilocarpine*** - **Pilocarpine** is a **direct-acting muscarinic agonist** that contracts the **ciliary muscle**. - Contraction of the ciliary muscle leads to **accommodation spasm** and a forward movement of the **iris-lens diaphragm**, which also helps to open the **trabecular meshwork**, facilitating aqueous outflow. *Timolol* - **Timolol** is a **beta-blocker** that reduces aqueous humor production by blocking beta-adrenergic receptors on the ciliary epithelium. - It does not directly affect the **ciliary muscle** or cause accommodation spasm. *Dorazolamide* - **Dorzolamide** is a **carbonic anhydrase inhibitor** that reduces aqueous humor production. - Its mechanism of action does not involve the ciliary body's mechanical action and therefore does not cause **accommodation spasm**. *Latanoprost* - **Latanoprost** is a **prostaglandin analog** that increases uveoscleral outflow of aqueous humor. - It does not directly affect the ciliary muscle's contraction or cause **accommodation spasm**.

Q: Which of the following statements about clonidine is incorrect?

First line for AMI. ***First line for AMI*** - Clonidine is **not first-line** for **Acute Myocardial Infarction (AMI)** as it can cause **bradycardia** and **hypotension**, potentially worsening cardiac output. - First-line AMI treatments include **thrombolytics**, **antiplatelet agents** (aspirin), **beta-blockers**, and **ACE inhibitors** for optimal cardiac protection. *Alpha 2 receptor agonist* - Clonidine is indeed an **alpha-2 adrenergic receptor agonist** that acts centrally in the **medulla oblongata**. - It reduces **sympathetic outflow** from the CNS, leading to decreased **heart rate**, **blood pressure**, and **peripheral vascular resistance**. *Sudden withdrawal causes rebound hypertension* - Abrupt clonidine discontinuation causes dangerous **rebound hypertension** due to sudden loss of **sympathetic inhibition**. - **Gradual tapering** over 1-2 weeks is essential to prevent this potentially life-threatening complication. *Controls loose motions due to diabetic neuropathy* - Clonidine effectively treats **diabetic diarrhea** by stimulating **alpha-2 receptors** in the enteric nervous system. - It **slows intestinal transit** and **enhances fluid absorption**, making it useful for **autonomic neuropathy-related** gastrointestinal symptoms.

Q: Muscarinic cholinergic receptors are seen at all sites, except?

Neuromuscular junction. ***Neuromuscular junction*** - The **neuromuscular junction** primarily contains **nicotinic cholinergic receptors**, not muscarinic receptors. - Activation of these nicotinic receptors by acetylcholine causes muscle contraction. *Stomach* - The stomach contains **muscarinic M3 receptors** which mediate gastric acid secretion and smooth muscle contraction. - Activation by acetylcholine via the vagus nerve promotes digestion. *CNS* - The **central nervous system** has various subtypes of **muscarinic receptors (M1-M5)** distributed throughout, playing roles in learning, memory, and motor control. - These receptors modulate neuronal excitability and neurotransmitter release. *Glands* - Most exocrine glands (e.g., salivary, lacrimal, sweat glands) are richly supplied with **muscarinic receptors**, primarily **M3**. - Activation leads to increased glandular secretion.

Q: Which urinary bladder spasmolytic has local anesthetic properties?

Oxybutynin. ***Oxybutynin*** - Possesses both **anticholinergic properties** (bladder smooth muscle relaxation) and **direct local anesthetic properties**, which contribute to its spasmolytic effect on the detrusor muscle. - The **local anesthetic action** directly reduces bladder detrusor muscle contractions, explaining its efficacy in treating urge incontinence and overactive bladder. - This dual mechanism makes it unique among bladder spasmolytics. *Tamsulosin* - Is an **alpha-1 adrenergic receptor blocker** used for benign prostatic hyperplasia (BPH) by relaxing smooth muscle in the prostate and bladder neck. - Does **not have local anesthetic properties** and is not a bladder detrusor spasmolytic. *Terazosin* - Also an **alpha-1 adrenergic receptor blocker**, similar to tamsulosin, used for BPH and hypertension. - Acts via **vascular and prostatic smooth muscle relaxation**, without local anesthetic or bladder spasmolytic effects. *Yohimbine* - Is an **alpha-2 adrenergic receptor antagonist** known for increasing sympathetic outflow. - Does **not have bladder spasmolytic effects** or local anesthetic properties.

Q: Which of the following is not a recognized use of alpha-2-agonists?

Benign Hyperplasia of prostate. ***Correct Answer: Benign Hyperplasia of prostate*** - Alpha-2-agonists are **NOT** used to treat **benign prostatic hyperplasia (BPH)**; this condition is typically managed with **alpha-1-blockers** (e.g., tamsulosin, alfuzosin) or 5-alpha-reductase inhibitors. - Alpha-1-blockers relax the smooth muscle in the prostate and bladder neck, improving urine flow, which involves a different receptor mechanism than alpha-2-agonists. - Alpha-2-agonists would not provide therapeutic benefit for BPH. *Incorrect: Glaucoma* - Alpha-2-agonists (e.g., **brimonidine**, **apraclonidine**) **are** used to treat **glaucoma** by reducing aqueous humor production and increasing uveoscleral outflow. - This action helps to **lower intraocular pressure**, a primary goal in glaucoma management. *Incorrect: Hypertension* - Central-acting alpha-2-agonists (e.g., **clonidine**, **methyldopa**) **are** used as **antihypertensive agents**. - They reduce sympathetic outflow from the central nervous system, leading to decreased heart rate, vasodilation, and consequently, **lower blood pressure**. *Incorrect: Sedation* - Alpha-2-agonists like **dexmedetomidine** and **clonidine** **are** commonly used for **sedation** in critically ill patients, especially in intensive care units. - They produce sedation, analgesia, and anxiolysis without causing significant respiratory depression, making them valuable in certain clinical settings.

Q: Which of the following is the prototypical sympathomimetic agent with both alpha and beta-adrenergic activity?

Epinephrine. ***Epinephrine*** - Epinephrine (adrenaline) is a potent direct-acting **sympathomimetic** that stimulates both **alpha and beta-adrenergic receptors**. - Its diverse effects on the cardiovascular, respiratory, and other systems make it the prototypical agent for demonstrating both receptor activities. *Norepinephrine* - While norepinephrine (noradrenaline) also acts on **alpha and beta-1 receptors**, its affinity for **beta-2 receptors** is significantly lower than epinephrine. - This results in a predominant effect on **vasoconstriction** and cardiac contractility rather than bronchodilation or peripheral vasodilation. *Isoproterenol* - Isoproterenol is a **non-selective beta-adrenergic agonist**, meaning it primarily stimulates **beta-1 and beta-2 receptors**. - It has minimal or no activity at **alpha-adrenergic receptors**, differentiating it from epinephrine's mixed activity. *Dopamine* - Dopamine's effects are **dose-dependent**; at low doses, it primarily stimulates **dopamine receptors** and at moderate doses, it activates **beta-1 receptors**. - At high doses, it can stimulate **alpha-adrenergic receptors**, but its primary and distinguishing characteristic is its agonism at **dopamine receptors**, which epinephrine does not share.

Question 1

Botulinum toxin acts on

Accepted Answer

Synapse

Answer

Smooth muscle of intestine

Answer

Central nervous system

Answer

Sensory nerves

Question 2

Which class of drugs does botulinum toxin mimic in its action?

Accepted Answer

Anticholinergics

Answer

Adrenergics

Answer

Antiadrenergic

Answer

Cholinergics

Question 3

Which of the following is a benzylisoquinoline muscle relaxant?

Accepted Answer

Doxacurium

Answer

Rocuronium

Answer

Pancuronium

Answer

Vecuronium

Question 4

Besides its properties of decreasing intraocular pressure, timolol is preferred in the treatment of glaucoma because it

Accepted Answer

Produces no miosis

Answer

Is a selective beta-adrenoceptor blocker

Answer

Increases outflow of aqueous humor

Answer

Possesses membrane stabilizing activity

Question 5

Which antiglaucomatous drug is known to cause spasm of accommodation?

Accepted Answer

Pilocarpine

Answer

Timolol

Answer

Dorzolamide

Answer

Latanoprost

Question 6

Which of the following statements about clonidine is incorrect?

Accepted Answer

First line for AMI

Answer

Alpha 2 receptor agonist

Answer

Sudden withdrawal causes rebound hypertension

Answer

Controls loose motions due to diabetic neuropathy

Question 7

Muscarinic cholinergic receptors are seen at all sites, except?

Accepted Answer

Neuromuscular junction

Answer

Stomach

Answer

CNS

Answer

Glands

Question 8

Which urinary bladder spasmolytic has local anesthetic properties?

Accepted Answer

Oxybutynin

Answer

Tamsulosin

Answer

Terazosin

Answer

Yohimbine

Question 9

Which of the following is not a recognized use of alpha-2-agonists?

Accepted Answer

Benign Hyperplasia of prostate

Answer

Glaucoma

Answer

Hypertension

Answer

Sedation

Question 10

Which of the following is the prototypical sympathomimetic agent with both alpha and beta-adrenergic activity?

Accepted Answer

Epinephrine

Answer

Isoproterenol

Answer

Norepinephrine

Answer

Dopamine

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?